Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.?
Oklahoma Medical Research Foundation has developed a highly effective and safe therapeutic for the treatment of glioblastoma. The compound, OKN-007, has the unique ability to cross the blood-brain barrier and has been successfully shown to decrease both tumor size and tumor vasculature in animal models of glioblastoma.
Hyalose, LLC is a biotechnology company focused on the commercialization of unique recombinant technologies for producing Hyaluronic Acid (HA), an important biomolecule for many healthcare and cosmetic applications.
Otologic Pharmaceutics, Inc. (OP) is an Oklahoma-headquartered organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balanced health.
DormaTarg is a pharmaceutical company developing a series of small molecule oncology therapeutics that inhibit recurrence in metastasis prone cancers, with an initial focus on Triple Negative Breast Cancer.
EpimedX, LLC is an Oklahoma-based biotechnology company with the mission to develop Gene Regulation Therapy ? a promising technology that is expected to provide a safe, cost-effective and permanent treatment for sickle cell disease, beta-thalassemia and malaria without dangerous or harmful side effects.
Selexys Pharmaceuticals? pioneering work on the molecular mechanisms of inflammation has led to breakthroughs in novel therapeutics for inflammatory and thrombotic diseases and positioned Selexys with strong scientific underpinnings.
Moleculera Labs provides personalized clinical testing services for individuals suspected of suffering from PANDAS/PANS, which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders (OCD) and sometimes Autism Spectrum Disorders.
Charlesson, an Oklahoma-based pharmaceutical company, is actively engaged in the development of therapeutics for treating debilitating ophthalmic diseases. Their product pipeline includes pharmaceutical treatments for Age-Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammation, Angiogenesis, and systemic diabetes.